Tango Therapeutics (NASDAQ:TNGX) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Tango Therapeutics (NASDAQ:TNGX) in a research report report published on Wednesday morning, MarketBeat reports. The brokerage issued an overweight rating and a $46.00 price objective on the stock.

Other analysts have also recently issued reports about the stock. Raymond James Financial cut shares of Tango Therapeutics to a “hold” rating in a research note on Thursday, June 25th. HC Wainwright boosted their price target on shares of Tango Therapeutics from $27.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Citigroup reaffirmed a “buy” rating on shares of Tango Therapeutics in a report on Monday, April 27th. Wolfe Research set a $35.00 price objective on Tango Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 8th. Finally, UBS Group set a $55.00 price objective on Tango Therapeutics in a research note on Thursday, May 14th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $42.15.

Tango Therapeutics Stock Up 3.3%

Shares of TNGX opened at $28.56 on Wednesday. Tango Therapeutics has a twelve month low of $5.77 and a twelve month high of $34.39. The stock has a market cap of $4.13 billion, a PE ratio of -34.41 and a beta of 1.12. The business’s 50-day moving average price is $26.66 and its 200-day moving average price is $19.95.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, meeting analysts’ consensus estimates of ($0.32). Analysts expect that Tango Therapeutics will post -1.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Tango Therapeutics

In related news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total transaction of $798,930.00. Following the transaction, the insider directly owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 81,000 shares of company stock worth $1,989,630. Company insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TNGX. Global Retirement Partners LLC purchased a new stake in shares of Tango Therapeutics in the 4th quarter valued at $35,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after purchasing an additional 4,464 shares during the period. ANTIPODES PARTNERS Ltd purchased a new position in Tango Therapeutics in the 4th quarter worth $40,000. State of Wyoming bought a new stake in Tango Therapeutics in the first quarter worth $128,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Tango Therapeutics by 52.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after purchasing an additional 2,243 shares during the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.